Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.57 |
| ▸ | GAA | P10253 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30287924 | 0.83 | HIF1A (0.74) | HIF1AALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL10388545 | 0.83 | HIF1A (0.74) | HIF1AALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL28906915 | 0.82 | HIF1A (0.64) | HIF1AALDH1A1MAPK1TP53LMNA | |
| SCHEMBL2979268 | 0.81 | HIF1A (0.62) | HIF1AALDH1A1HSD17B10MAPK1LMNA | |
| Hydrochloric Acid SCHEMBL2987335 | 0.79 | HIF1A (0.61) | HIF1AALDH1A1MAPK1LMNAMEN1 | |
| SCHEMBL8782838 | 0.78 | MAOA (0.53) | ALDH1A1MAPK1CYP3A4TP53MEN1 | |
| SCHEMBL2463521 | 0.78 | MAPT (0.68) | HIF1AALDH1A1CYP2D6LMNAMEN1 | |
| SCHEMBL1645842 | 0.78 | HIF1A (0.58) | HIF1AALDH1A1HSD17B10MAPK1CYP1A2 | |
| SCHEMBL11535127 | 0.76 | MAOA (0.51) | ALDH1A1MAPK1MEN1KMT2ATDP1 | |
| SCHEMBL4820844 | 0.76 | HIF1A (0.72) | HIF1AALDH1A1HSD17B10MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | claimed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | claimed |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2019-01-24 | — | — | US | disclosed |
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY INC (US) | 2016-05-12 | — | — | US | disclosed |
| US-9173886-B2 | Antiviral compounds and methods of use thereof | TRANA DISCOVERY, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TRANA DISCOVERY, INC (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2012079032-A2 | COMPOSITIONS AND METHODS OF TREATING DRUG-RESISTANT RETROVIRAL INFECTIONS | TRANA DISCOVERY, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2011113060-A2 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TRANA DISCOVERY, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10098887-B2 | Antiviral compounds and methods of use thereof | TYMP, MAVS, ZC3HAV1 | HIF1A 1951/4885ALDH1A1 2506/4885HSD17B10 3791/4885 |
| US-20160129006-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | HIF1A 1951/4885ALDH1A1 2506/4885HSD17B10 3791/4885 |
| US-20130071353-A1 | Antiviral Compounds and Methods of Use Thereof | TYMP, MAVS, ZC3HAV1 | HIF1A 1951/4885ALDH1A1 2506/4885HSD17B10 3791/4885 |
| US-20190022100-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USE THEREOF | TYMP, MAVS, ZC3HAV1 | HIF1A 1951/4885ALDH1A1 2506/4885HSD17B10 3791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.